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The present invention provides methods and formulations for 
optimizing the anti-cancer and anti-HIV activities of a camp 
tothecin drug, including camptothecin and its related analogs 
including 9-aminocamptothecin and 9-nitrocamptothecin. 
The invention involves methodologies and formulations that 
limit human serum albumin-mediated reduction of the anti 
cancer and anti-HIV effects of the camptothecins, and the 
methods and formulations provide combination therapies in 
Which binding of the camptothecin agent to human serum 
albumin can be modulated by the administration of a com 
peting agent that also binds human serum albumin. Reduced 
camptothecin drug binding to human serum albumin can 
result in elevated camptothecin free drug levels and thus 
improve the effectiveness of treatment regimens involving 
these drugs. Further agents such as methotrexate andAZT can 
also be used in cancer and HIV-positive patients employing 
camptothecin drugs. 
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METHODS AND COMPOSITIONS FOR 
OPTIMIZING BLOOD AND TISSUE 
STABILITY OF CAMPTOTHECIN AND 
OTHER ALBUMIN-BINDING THERAPEUTIC 
COMPOUNDS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the bene?t of US. Provisional 
Application Ser. No. 60/276,908, ?led Mar. 20, 2001. 
FIELD OF THE INVENTION 
The invention relates in general to methods of optimizing 
camptothecin and other albumin-binding compounds for 
therapeutic use, and in particular to a method of using human 
serum albumin binding compounds to increase the stability 
and effectiveness in humans of camptothecin compounds and 
other albumin-binding compounds Which have been shoWn to 
possess important therapeutic attributes, such as anti-cancer 
activity, in murine cells or other in vitro studies, but Which 
have been far less successful in humans due to rapid lack of 
stability in human plasma. In addition, the invention relates to 
the use of human serum albumin binding compounds in con 
junction With camptothecin compounds and other therapeutic 
agents that bind to human serum albumin in methods of 
treating or enhancing treatments against diseases such as 
cancer and/ or HIV. 
BACKGROUND OF THE INVENTION 
Camptothecin (CPT) has been shoWn to inhibit the groWth 
of a variety of animal and human tumors. Camptothecin and 
its related congeners display a unique mechanism of action: 
they stabiliZe the covalent binding of the enZyme topoi 
somerase I (topo I), an intranuclear enZyme that is overex 
pressed in a variety of tumor lines, to DNA. This drug/en 
Zyme/DNA complex leads to reversible, single strand nicks 
that, according to the fork collision model, are converted to 
irreversible and lethal double strand DNA breaks during rep 
lication. Therefore, due to the mechanism of its cytotoxicity, 
CPT is S-phase speci?c, indicating that it is only toxic to cells 
that are undergoing DNA synthesis. Rapidly replicating cells 
like cancerous cells spend more time in the S-phase relative to 
healthy tissues. Thus, the overexpression of topo I combined 
With the faster rate of cell replication provide a limited basis 
for selectivity via Which camptothecins can effect cytoxicity 
on cancerous cells rather than healthy ho st tissues. It is impor 
tant to note that due to the S-phase speci?city of the camp 
tothecins, optimal inhibition of topo I requires continuous 
exposure to the camptothecin agent. 
A closed alpha-hydroxy lactone (E) ring of CPT is an 
essential structural feature. An intact ring is necessary for the 
diffusion of the electroneutral form of the drug across mem 
brane barriers and into cells by passive transport and, directly 
relevant to its in vivo anti-tumor potency, is required for the 
successful interaction of CPT With the topoisomerase I target. 
This essential lactone pharmacophore hydrolyZes under 
physiological conditions (pH 7 or above) and, therefore, the 
drug can exist in tWo distinct forms: 1) the biologically active, 
ring-closed lactone form; and 2) the biologically-inactive, 
ring-open carboxylate form of the parent drug. Unfortunately, 
under physiological conditions the drug equilibrium favors 
hydrolysis and, accordingly, the carboxylate form of the 
camptothecin drug persists. The labile nature of this alpha 
hydroxy lactone pharmacophore has signi?cantly compro 
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mised the clinical utility of the camptothecins, as continuous 
exposures to the active lactone form are requisite for e?icacy 
purposes. 
In human blood and tissues, the camptothecins exist in a 
equilibrium of active lactone form vs. inactive carboxylate 
form and the directionality of this equilibrium can be greatly 
affected by the presence of human serum albumin (HSA). 
Time-resolved ?uorescence spectroscopic measurements 
taken on the intensely ?uorescent camptothecin lactone and 
camptothecin carboxylate species have provided direct infor 
mation on the differential nature of these interactions With 
HSA. The lactone form of camptothecin binds to HSA With 
moderate af?nity yet the carboxylate form of camptothecin 
binds tightly to HSA, displaying a 150-fold enhancement in 
its a?inity for this highly abundant serum protein. Thus, When 
the lactone form of camptothecin is added to a solution con 
taining HSA, the preferential binding of the carboxylate form 
to HSA drives the chemical equilibrium to the right, resulting 
in the lactone ring hydrolyZing more rapidly and completely 
than When camptothecin is in an aqueous solution Without 
HSA. In turn, this effect has negatively impacted the topoi 
somerase I inhibitory activity of many camptothecins and, by 
extension, negatively affects their clinical utility. 
The important role that HSA plays in the stability of the 
camptothecins varies relative to drug structure. For drugs 
such as camptothecin and 9-aminocamptothecin, HSA func 
tions as a biological sink for the carboxylate form. As a result, 
in Whole human blood, 5.3% of camptothecin and only 0.5% 
of 9-aminocamptothecin remain in the lactone form at equi 
librium. In contrast, A, B-ring substitutions of CPT, speci? 
cally at the 7- and 10-positions, can inhibit the preferential 
binding interactions betWeen the camptothecin carboxylate 
and HSA. Accordingly, camptothecin congeners such as 
topotecan and SN-38, the biologically active form of the 
prodrug CPT-11, display lactone levels at equilibrium of 
11.9% and 19.5%, respectively. Ultimately, by modulating 
the circulatory and tissue levels of free and active camptoth 
ecin drug, HSA can negatively impact the anti-cancer e?icacy 
of the camptothecin agent. 
The effect of serum albumins on camptothecins also differs 
markedly betWeen loWer vertebrates and humans and this 
variance has obscured the judicious selection of analogs for 
advancement to clinical trials. These interspecies difference 
have lead to signi?cant anomalies When the data from animal 
models and clinical studies are compared. In particular, 
9-aminocamptothecin has displayed striking activity in 
murine models bearing brain tumors. HoWever, the pharma 
cokinetics of 9-aminocamptothecin in mice are quite differ 
ent from those in humans; notably, 9-aminocamptothecin 
lactone levels are approximately 100-fold higher in murine 
blood relative to human blood. This discrepancy is due to the 
reduced binding of the carboxylate form of 9-aminocamp 
tothecin to murine albumin. The logical extension of this 
?nding is that approximately 100-fold more free lactone, 
Which is able to cross cell membranes or the blood-brain 
barrier, is present in the mouse than it is in humans. The 
clinical relevance of this interspecies variation is underscored 
by a recent trial: 99 brain cancer patients Were treated intra 
venously With 9-aminocamptothecin; the therapy Was grossly 
ineffective (one partial responder) due to the likelihood that 
99.5% of the drug Was in the carboxylate form, bound to HSA 
and unable to transverse the blood-brain barrier. 
The inherent blood instability of camptothecin has resulted 
in an extensive research effort to surmount the problem. 
Efforts to realiZe a blood stable camptothecin agent With 
potent anti-tumor activity have been primarily focused on 
formulation, such as liposomal preparations of the drug, and 
US 7,69l,872 B2 
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rational drug design, such as the development of the class of 
beta-hydroxy lactone camptothecins known as the 
homocamptothecins. The Work described herein describes a 
third approach to maintaining a potent and more blood stable 
camptothecin congener: the modulation of camptothecin 
drug binding to HSA by implementing competing molecules 
that also bind HSA. 
The camptothecins are not unique in their ability to bind 
albumin, as a variety of small molecules interact With this 
protein. A relatively large protein, 67 kD, albumin is distrib 
uted both in the plasma and in the interstitial ?uid. Being one 
of the most abundant plasma proteins, its circulatory level 
ranges from 35 to 50 mg/ml (approximately 0.6 mM). The 
principal biological function of HSA is to maintain colloid 
osmotic pressure in the vascular system and to transport fatty 
acids and bilirubin. HoWever, by hydrophobic and/or ionic 
interactions, a variety of small molecules bind tightly to albu 
min. Electroneutral and basic drugs may bind to albumin by 
hydrophobic binding interactions, and, as albumin has a net 
cationic charge, anionic drugs bind avidly to albumin via 
electrostatic interactions. Albumin possesses tWo Well-char 
acteriZed binding pockets, as Well as other general binding 
sites. Site I is knoWn as the Warfarin binding site, Which also 
binds drugs such as phenylbutaZone, sulfonamides, pheny 
toin, and valproic acid. Site 11 is referred to as the diaZepam 
site, Which is also the binding site for benZodiaZepines, tryp 
tophan, ibuprofen, naproxen, octanoic acid, clo?bric, iopan 
ice, probenecid, semi-synthetic penicillins and medium chain 
fatty acids. Other general binding sites include sites for biliru 
bin, digitoxin and a variety of fatty acids. Recent X-ray crys 
tallography and competition data obtained by the present 
inventors reveal that camptothecin carboxylate preferentially 
associates With a characteriZed drug binding site in subdo 
main IB, Which overlaps With one of the main long-chain fatty 
acid binding sites, protoporphyrin and other drugs and com 
pounds, although it possesses secondary a?inity to binding 
sites I and II. Interestingly, in vivo small molecule binding to 
albumin is saturable at therapeutically relevant drug levels. 
The ability of human serum albumin to avidly bind to a 
variety of small molecules offers the possibility of competi 
tively attenuating the negative effects human serum albumin 
on the in vivo anti-cancer and/ or anti-HIV activity of camp 
tothecin compounds and numerous other compounds such as 
camptothecin that have extremely high binding af?nity for 
human serum albumin. 
HoWever, no prior methods have recogniZed or attempted 
to deal With the problem caused by the human serum albumin 
binding activity, and thus methods and compositions are 
needed Which can attenuate the negative effects of human 
serum albumin on the stability of compounds such as camp 
tothecin compounds, e.g., camptothecin or 9-aminocamp 
tothecin, and other compounds or drugs, such as protease 
inhibitors, Which have a high a?inity for human serum albu 
min. 
SUMMARY OF THE INVENTION 
It is thus an object of the present invention to utiliZe human 
serum albumin binding molecules in a method of achieving 
increased stability of compounds, such as camptothecin com 
pounds, Which have a high a?inity for human serum albumin 
and Which are thus generally less effective than optimal When 
administered in the human bloodstream. 
It is also an object of the present invention to provide 
therapeutic methods of administering compounds such as 
camptothecin that have a high a?inity for albumin in humans 
by adding a human serum albumin binding compound With 
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the ability to bind to one or more binding sites on human 
serum albumin so that the compounds having high a?inity for 
albumin can become more stable When administered and thus 
are far more effective than therapeutic drugs administered 
Without such additive binding compounds. 
It is still further an object of the present invention to pro 
vide a method of treating cancer Wherein a camptothecin 
compound is administered in conjunction With an appropriate 
human serum albumin binding agent. 
It is still further an object of the present invention to pro 
vide a method of treating HIV infection Wherein a protease 
inhibitor is administered in conjunction With an appropriate 
human serum albumin binding agent. 
It is even further an object of the present invention to 
provide a Wide range of compounds Which can effectively be 
used to increase and optimiZe the stability of camptothecin 
compounds When administered to humans. 
It is even further an object of the present invention to 
provide a method of utiliZing an agent Which can bind to one 
or more sites on human serum albumin and yet Which also has 
anti-tumor or tumoricidal effects and Which can thus be 
administered in conjunction With camptothecin compounds 
so as to even further enhance the cancer-?ghting properties of 
camptothecin compounds. 
It is even further an object of the present invention to 
provide a method of utiliZing an agent Which can bind to one 
or more sites on human serum albumin and yet Which also has 
anti-HIV abilities and Which can thus be administered in 
conjunction With protease inhibitors so as to even further 
enhance the HIV-?ghting properties of protease inhibitors. 
It is even further an object of the present invention to 
provide a method of utilizing an agent Which can bind to one 
or more sites on human serum albumin and yet Which also has 
anti-HIV effects and Which can thus be administered in con 
junction With camptothecin compounds so as to even further 
enhance the HIV-?ghting properties of camptothecin com 
pounds. 
These and other objects are achieved via the present inven 
tion Which implements combination therapy consisting of 
competitor molecules that can bind human serum albumin 
(HSA) and thereby inhibit albumin binding of drugs Which 
have a high binding a?inity for human serum albumin, such as 
camptothecin compounds and protease inhibitors, and thus 
increase the effectiveness and safety of these drugs When 
administered to humans. This invention overcomes multiple 
obstacles that have been associated With therapies based on 
drugs such as camptothecin Which have high binding a?inity 
for human albumin. First, as a result of this binding interac 
tion, the competitor effects elevated free camptothecin drug 
levels in human blood and tissues. Secondly, this invention 
also overcomes the negative effects of human serum albumin 
on the in vivo stability of some camptothecin drugs, such as 
camptothecin, 9-aminocamptothecin, and 9-nitrocamptoth 
ecin. For camptothecin, 9-aminocamptothecin, and 9-nitro 
camptothecin, it has been demonstrated that the inactive, 
carboxylate form of the drug binds tightly to human serum 
albumin. This binding promotes a shift in the lactone/car 
boxylate equilibrium to favor the formation of the carboxy 
late form of the drug. A competitor molecule that reduces the 
binding of camptothecin carboxylate to human serum albu 
min can shift the drug equilibrium to favor re-lactoniZation of 
the camptothecin agent. As the equilibrium shifts to favor the 
formation of the active, lactone form of the camptothecin 
agent, the anti-tumor activity of the drug is preserved. Third, 
preservation of the electroneutral, lactone form of the camp 
tothecin agent should enhance the cellular uptake and cellular 
concentration of the agent, as on the electroneutral drug spe 
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cies may transverse the plasma membrane. Thus, the present 
invention provides a method for improving camptothecin 
based anti-cancer and/ or anti-HIV therapies. 
The competitive displacement of the camptothecin drug 
can occur by allosteric inhibition or by direct binding of the 
small molecule to the camptothecin binding pocket(s). The 
camptothecin agents herein can include camptothecin, 9-ni 
trocamptothecin, 9-aminocamptothecin, SN-38, the [3-hy 
droxy-o-lactone camptothecins, such as the homocamptoth 
ecins and homosilatecans, and any other camptothecin agent 
that physically interacts With human serum albumin either in 
its lactone or carboxylate form. The competing small mol 
ecule can include a diverse array of molecular entities that 
exhibit a binding a?inity for human serum albumin. 
Examples include aspirin, ibuprofen, AZT, methotrexate, 
Warfarin, and the medium chain triglycerides, such as capry 
late. The patient may be administered a single competitor or 
a series of distinct competitors, Which can be administered 
individually or as a mixture. The camptothecin agent and the 
competitor(s) can be co-administered or administered sepa 
rately in order to enhance the desired therapeutic effect. The 
camptothecin agent and the competitor(s) can be adminis 
tered orally and/ or intravenously in order to enhance the 
desired therapeutic effect. 
Another important aspect of the present invention is the use 
of this type of drug displacement therapy utiliZing binding 
compounds for albumin for any drug or other bene?cial com 
pound Which Will be amenable to improvements in safety (by 
loWering the effective dose through displacement) or ef?cacy 
by alloWing a higher concentration of the active principle 
during therapeutic treatment. 
Accordingly, the present invention also is directed to the 
addition of an albumin-binding compound to improve the 
effectiveness and/or safety of drugs or therapeutic com 
pounds Which, other than camptothecin, also shoW binding 
a?inity for human serum albumin. Of the top 200 pharma 
ceuticals as of 1999, a substantial number have high binding 
a?inity for albumin and in most cases become at least 97% 
bound to albumin in the human patient. As a result, the effec 
tiveness of these drugs can be severely limited in some cases, 
or far greater doses are necessary to achieve a desired result, 
and these inordinately higher doses almost invariably lead to 
greater drug side-effects Which can often negate the therapeu 
tic bene?t of the drugs. 
The high binding a?inity in many drugs for albumin also 
has created problems in developing effective neW drugs 
because many drugs are tested ?rst in vitro or in environments 
outside the human body Wherein the presence of human 
serum albumin is not provided for. As a result, many neWly 
developed drugs Work extremely Well in these initial tests, but 
then are rendered less effective or entirely useless When 
administered to human patients because of their high a?inity 
to human serum albumin Which has not been accounted for. In 
addition to the camptothecin compounds set forth in detail 
herein, numerous other drugs Will also be improved through 
introduction of albumin binding compounds in accordance 
With the present invention, including drugs such as protease 
inhibitors Which have shoWn some initial effectiveness in 
anti-HIV treatment. In accordance With the present invention, 
the anti-HIV treatments that employ protease inhibitors With 
a high binding af?nity for albumin Will be greatly enhance 
When such treatments Will be administered in conjunction 
With administration of an effective amount of the albumin 
binding compounds in accordance With the present invention. 
The present invention thus provides a method of utiliZing 
the ability of human serum albumin to avidly bind to a variety 
of small molecules so as to competitively attenuate or elimi 
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nate negative effects of human serum albumin on the in vivo 
anti-cancer and/or anti-HIV capabilities of camptothecin 
compounds and other therapeutic compounds such as pro 
tease inhibitors Which have high a?inity for human serum 
albumin via one or more binding sites on serum albumin. 
Because the human serum albumin binding sites and their 
a?inity for many small molecules have been Well character 
iZed, many of these small molecules are ideal for in vivo 
administration and Will be useful in the present invention and 
can be utiliZed When it is necessary to target one or more 
particularbinding sites. A number of suitable small molecules 
can thus be employed as human serum albumin binding com 
petitors to effect the displacement of camptothecin drugs and 
compounds, either in the lactone or carboxylate form, and of 
other therapeutic compounds, such as protease inhibitors, 
Which also have high binding a?inity to human serum albu 
min. Generally, it is contemplated that treatment With albu 
min binding compounds in accordance With the present 
invention Will be particularly effective With those drugs or 
other therapeutic compounds that exhibit about 90% or 
greater binding With HSA. 
X-ray crystallographic experiments performed using appa 
ratuses and methods previously described in patents such as 
U.S. Pat. No. 4,833,233, U.S. Pat. No. 4,886,646 and Us. 
Pat. No. 5,585,466, incorporated herein by reference, have 
revealed the camptothecin binding sites to be overlapping 
With long-chain fatty acids and ibuprofen consistent With the 
solution chemistry. 
Inhibiting the binding of the camptothecin agent to human 
serum albumin, or other therapeutic compounds to human 
serum albumin, Will thus enhance free drug levels of that 
therapeutic compound in the blood and tissue. Given that a 
diverse assortment of small molecules binds to HSA, these 
small molecules may be administered singly or as a mixture 
With the camptothecin agent or other therapeutic compound 
to enhance their free drug levels. Moreover, via inhibiting the 
binding of the carboxylate form of a camptothecin drug, a 
shift in the equilibria occurs that favors the formation of the 
biologically active and electroneutral lactone species. Lastly, 
as many of these small molecules exhibit pharmacological 
activity, they may be utiliZed dually for their competitive 
binding to human serum albumin and for their desired in vivo 
effect. Thus, agents such as methotrexate, AZT, and a number 
of additional small molecules as set forth beloW may be used 
to enhance the free drug levels of camptothecin or other 
therapeutic drugs, such as protease inhibitors, and substan 
tially enhance their respective biological effects in humans. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1-6 re?ect test results With regard to camptothecin 
compounds (CPT) and competitor binding agents. 
FIG. 1 is a graphic representation of competitor binding 
tests betWeen CPT and ibuprofen. 
FIG. 2 is a graphic representation of competitor binding 
tests betWeen hCPT and ibuprofen. 
FIG. 3 is a graphic representation of competitor binding 
tests betWeen SN38 and Caprylic Acid. 
FIG. 4 is a graphic representation of competitor binding 
tests betWeen CPT and Caprylic Acid. 
FIG. 5 is a graphic representation of competitor binding 
tests betWeen SN38 and HSA. 
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FIG. 6 is a graphic representation of competitor binding 
tests betWeen hCPT and Caprylic Acid. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
For the purpose of clarity in the detailed description of the 
invention, the following de?nitions and detailed description 
of the invention are provided beloW. 
Hydrolysis of the Camptothecins 
The [3-hydroxy-6-lactone members of the camptothecin 
class of anti-cancer drugs exhibit the folloWing chemical 
equilibrium at pH 7 and above: 
Figure l: CPT Hydrolysis at Physiological pH 
pH : 7.4 
CPT Carboxylate 
The electroneutral lactone species, as depicted on the left, 
represents the biologically active form of the camptothecin 
agent. The carboxylate species, as depicted on the right, rep 
resents the biologically inactive forrn of the agent. The [3-hy 
droxy-o-lactone camptothecins, also knoWn as the 
homocamptothecins and homosilatecans, also undergo 
hydrolysis, hoWever, there is no chemical equilibrium as the 
reaction is not reversible under normal physiological condi 
tions. The hydrolysis of the [3-hydroxy-6-lactone camptoth 
ecins is detailed above. 
HSA Binding of the Carboxylate Species 
The carboxylate species of the camptothecin agent may 
bind HSA at speci?c, de?ned sites, as detailed by crystallo 
graphic and displacement studies, and may also bind directly 
to HSA at non-speci?c sites that have yet to be clearly 
de?ned. Binding may occur by hydrophobic and/or ionic 
interactions betWeen HSA and the camptothecin carboxylate 
form. 
HSA Binding of the Lactone Species 
The lactone species of the camptothecin agent may bind 
HSA at speci?c, de?ned sites, as detailed by crystallographic 
and displacement studies, and may also bind directly to HSA 
at non-speci?c sites that have yet to be clearly de?ned. Bind 
ing betWeen HSA and the camptothecin lactone form may 
occur by non-covalent means. 
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HSA Binding of the Competitor 
The competitor may bind to HSA at speci?c, de?ned sites, 
as detailed by crystallographic and displacement studies, and 
may also bind HSA at non-speci?c sites that have yet to be 
clearly de?ned. Binding betWeen the competitor and HSA 
may occur by covalent or non-covalent mechanisms. 
General De?nitions 
Before the present compositions and methods are disclosed 
and described, it is to be understood that this invention is not 
limited to speci?c drugs, human serum albumin selective 
ligands, pharmaceutical carriers, or administration regimens, 
as such may, of course, vary. It is also to be understoodthat the 
terminology used herein is for the purpose of describing 
particular embodiments only and is not intended to be limit 
ing. 
It must be noted that, as used in the speci?cation and the 
appended claims, the singular forms “a,” “an,” and “the” 
include plural referents unless the context clearly dictates 
otherWise. Thus, for example, reverence to a “a pharmaco 
logically active agent” includes mixtures of tWo or more such 
ligands, and the like. 
By the term “pharmacologically active agent” or “drug” as 
used herein is meant any chemical material or compound 
suitable for administration to a mammalian, preferably 
human, individual, Which induces a desired local or systemic 
effect. In general, this includes: anorexics; anti-infectives 
such as antibiotics and antiviral agents, including many peni 
cillins and cephalosporins; analgesics and analgesic combi 
nations, antiarrythmics; antiarthritics; antiasthmatic agents; 
anticholinergics; anticonvulsants; antidiabetic agents; antidi 
arrheals; antihelminthics, antihistamines; anti-in?ammatory 
agents; anti-migraine preparations; antinasuseants; antine 
oplastics; antiparkinsonism drugs; antipruritics; antipsychot 
ics; antipyretics; antisense agents; antispasmodics; cardio 
vascular preparations including calcium channel blockers 
and beta-blockers such as pindolol; antihypertensives; central 
nervous system stimulants; cough and cold preparations, 
including decongestants; diuretics; gastrointestinal drugs; 
sympathomimetics; hormones such as estradiol and steroids; 
hypnotics; immunosuppressives; muscle relaxants; parasym 
patholytics; psychostimulatants; sedatives; tranquilizers; 
vasodilators including general coronary, peripheral and cere 
bral; xanthine derivatives. 
As used herein, the term “competitor” refers to a chemical 
material or pharmacologically active agent suitable for 
administration to a mammalian, preferably human. The com 
petitor exhibits binding af?nity for serum albumin and, in 
general, includes: long chain fatty acids (Cm-C20; including 
oleic, palmitic, linoleic, stearic, arachidonic, and palmitole 
ic);medium chain fatty acids (C6-C14; including caprylate or 
octanoate); phospholipids (lysolecithins, oleoyllysophospha 
tidic acid, phosphatidylcholine, phosphatidylethanolamiine); 
eicosanoid derivatives (leukotrienes, thromboxanes, prostag 
landins A, E, F, and I); steroid hormones (cholesterol, test 
osterone, pregnenolone, cortisol, androsterone, indol, 
progesterone, estrogen); vitamin D (both monohydroxyvita 
min D and dihydroxyvitamin D); bile salts (lithocholate, 
chenodeoxycholate, deoxycholate, ursodeoxycholate, cho 
late, glycolitocholate, glycochenodeoxycholate, taurocheno 
doxycholate, glycodeoxycholate, glycocholate, taurocho 
late); bilirubins (bilirubin, biliverdin, xanthobilirubin, 
EZ-cyclobilirubin, o-bilirubin); porphyrins (hematin, proto 
porphyrin); Warfarin; salicylates, ibuprofen; prednisone; 
iophenoxate; sul?soxaZole; phenylbutaZone; oxphenylbuta 
Zone; digitoxin; indomethacin; tolbutamide; furosemide; 
phenytoin; chlorpropamide; chlorthiaZide; the penicillins (in 
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cluding oxacillin, benZylpenicillin); acetotriZoate; isulfobro 
mophthalein; deacetylcolchicine; dansylamide; dansyl 
glutamine; dansylsarcosine; indomethacin; 
phenylpropaZone; aZobenZene derivatives; sulfobromophtha 
lein; triiodobenZoate; benZodiaZepine (including diaZepam); 
?ufenamate; iopanoate; ethacrynate; panproxen; clo?brate; 
L-tryptophan; N-acetyl-L-tryptophan; 6-methyltryptophan; 
thyroxine; 3,5,3'-L-triiodothyronine; indole propionate; 
kynurenine; ethacrynate; panproxen; chlorophenoxyisobu 
tyrate; 3'aZido-3'-deoxythymidine; non-steroidal anti-in 
?ammatory agents containing ionized carboxyl groups; gos 
sypol; meso-2,3-dimercaptosuccinic acid; captopril; N-2 
mercaptoethyl-l ,2-diaminopropane; 
disul?ramacetaminophen, dis-dichlorodiamineplatinum 9II; 
pyridoxal 5'-pho sphate; aquocobalamin form of vitamin B 12; 
folate; ascorbate (and its oxidation product dehydroascor 
bate); melatonin; ot-melanotropin; gastrin; corticotropin and 
methotrexate. 
An “effective amount” of a pharmacologically active agent 
is intended to mean a nontoxic but su?icient amount of the 
agent, such that the desired prophylactic or therapeutic effect 
is produced. As Will be pointed out beloW, the exact amount of 
a particular agent that is required Will vary from subject to 
subject, depending on the species, age, and general condition 
of the subject, the severity of the condition being treated, the 
particular drug used and its mode of administration, and the 
like. In addition, other factors, such as an assay of patient 
albumin levels prior to administering the therapy and adjust 
ing the drug levels accordingly is often utiliZed to properly set 
a treatment regiment for a particular patient. 
Thus, it is not possible to specify an exact “effective 
amoun ” of any particular pharmacologically active agent. 
HoWever, an appropriate effective amount may be determined 
for any particular drug by one of ordinary skill in the art using 
only routine experimentation. 
By the term “pharmaceutically acceptable” to describe a 
carrier or excipient is meant a material that is not biologically 
or otherWise undesirable, i.e., the material may be adminis 
tered along With the selected pharmacologically active agent 
Without causing any desirable biological effects or interacting 
in a deleterious manner With any of the other components of 
the pharmaceutical composition in Which it is contained. 
The term “camptothecin drug” or “camptothecin com 
pound” is inclusive of camptothecins that contain either an 
E-ring ot-hydroxy lactone pharmacophore or an E-ring [3-hy 
droxy lactone pharmacophore, Which includes the 
homocamptothecins and homosilatecans. As used herein, the 
camptothecin analogs 9-aminocamptothecin, 10-hydroxy 
camptothecin, 10, 1 1-methylenedioxy-camptothecin, 9-nitro 
10,1 1 -methylenedioxycamptothecin, 9-chloro-10,1 1-meth 
ylenedioxycamptothecin, 9-amino-10,1 1 - 
methylenedioxycamptothecin, 9-nitrocamptothecin, 
topotecan, and other analogs of camptothecin, are collec 
tively referred to as camptothecin drugs or compounds. 
DESCRIPTION OF THE INVENTION 
The present invention accomplishes multiple tasks. First, 
administration of a HSA binding competitor elevates free 
camptothecin levels in blood and human tissues by inhibiting 
camptothecin drugs from binding to human serum albumin. 
Secondly, for those camptothecin drugs that bind human 
serum albumin in the carboxylate form, this invention induces 
a shift in the lactone carboxylate equilibrium that enhances in 
vivo drug lactone levels. Third, Enhanced free drug levels and 
elevated lactone levels in vivo result in greater cellular uptake 
and enhanced activity. 
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Under physiological conditions, the camptothecin drug 
exists in a equilibrium of the active lactone and inactive 
carboxylate forms. In humanblood and tissues, binding of the 
camptothecin drug to human serum albumin can occur When 
said drug is either in the biologically inactive, carboxylate 
form or in the biologically active, lactone form. Camptoth 
ecin, 9-aminocamptothecin, and 9-nitrocamptothecin bind 
human serum albumin predominantly in the carboxylate 
form. In contrast, SN-38, the biologically active agent of the 
camptothecin prodrug CPT-l 1, binds human serum albumin 
in the lactone form. Binding of the camptothecin drug, 
Whether in the carboxylate or lactone form, reduces the levels 
of free drug in the blood and tissue. 
As described above, the present invention relates to the use 
of human serum albumin binding molecules Which are 
administered in conjunction With camptothecin compounds 
in order to achieve greater stability in the human bloodstream 
and thus alloW for the camptothecin compounds to be more 
effective When administered in human treatment regimens. 
The invention thus contemplates therapeutic methods, such 
as methods to treat diseases such as cancer or HIV, Wherein 
camptothecin compounds are administered in humans in con 
junction With a suitable human serum albumin binding com 
pound. Even further, it is contemplated that the human serum 
albumin binding compound selected for use in accordance 
With the present invention Will ideally be one that additionally 
enhances the effect of the free camptothecin compounds. In 
this regard, agents such as methotrexate, AZT, and a number 
of additional small molecules as set forth beloW may be used 
to enhance free camptothecin drug levels and substantially 
enhance their respective biological effects in humans. 
The following is a list of molecules that bind human serum 
albumin and are thus contemplated for use in accordance With 
the present invention: 
Long Chain Fatty Acids (C l6-C2O) 
Oleic, palmitic, linoleic, stearic, arachidonic, and palmitoleic 
Note for fatty acids, at pH 7 they exist as salts, and thus may 
more accurately be de?ned not as palmitic acid but as 
palmitate. 
Medium Chain Fatty Acids (C6-Cl4) 
Phospholipids: 
Lysolecithins, oleoyllysophosphatidic acid, phosphatidyl 
choline, phosphatidylethanolamiine 
Eicosanoid derivatives: 
Leukotrienes, thromboxanes, prostaglandins A, E, F, andI 
Steroid hormones: 
Cholesterol, testosterone, pregnenolone, cortisol, androster 
one, indol, progesterone, estrogen 
Vitamin D: both monohydroxyvitamin D and dihydroxyvita 
min D. 
Bile Salts: Lithocholate, Chenodeoxycholate, Deoxycholate, 
Ursodeoxycholate, Cholate, Glycolitocholate, Glyco 
chenodeoxycholate, Taurochenodoxycholate, Glycode 
oxycholate, Glycocholate, Taurocholate 
Bilirubins: bilirubin, biliverdin, xanthobilirubin, EZ-cyclobi 
lirubin, o-bilirubin 
Gossypol (note high af?nity 1.1 e-7, competes With bilirubin, 
antibiotic, promotes fertility) 
Porphyrins: hematin, protoporphyrin 
Site I Ligands (domain IIA): bilirubin, Warfarin, salicylates, 
cyclic eicosanoids, hematin, G-dicarboxylic medium 
chain fatty acids, long-chain fatty acids, prednisone, iophe 
noxate (eliminated sloWly due to extremely high a?inity, 
contrast agent), salicylates, sul?soxaZole, WarfarinS-, phe 
nylbutaZone, digitoxin, indomethacin, tolbutamide, furo 
semide, phenytoin, chlorpropamide, chlorthiaZide, oxacil 
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lin, benZylpenicillin, acetotriZoate, phenol red, bromcresol 
green, brophenol blue, isulfobromophthalein, methyl 
orange, methyl red, evans blue, deacetylcolchicine, Phenol 
red, dansylalmide, dansylglutamine, dansylsarcosine, 
indomethacin, phenylpropaZone, bromcresol purple, 
aZobenZene derivatives, sulfobromophthalein, triiodoben 
Zoate, cibacron blue, various penicillins, benZodiaZepine, 
Site II Ligands (subdomain IIA): monocarboxylic medium 
chain fatty acids (C6-C14; in particular octanoate), diaZ 
epam (the 2,3-benZodiaZepines), ?ufenamate, iopanoate, 
ethacrynate, panproxen, chlorophenoxyisobutyrate (clo? 
brate), L-tryptophan, octanoate, thyroxine, N-Acetyl-L 
tryptophan, indole propionate, kynurenine, 6-methyltryp 
tophan, 3,5,3'-L-triiodothyronine, triiodobenZoate, 
ibuprofen, chloride ions, AZT (3'aZido-3'-deoxythymi 
dine, non-steroidal anti-in?ammatory agents containing 
ioniZed carboxyl groups (Li et al., 1988; WanWimolruk et 
al., 1991), oxphenylbutaZone 
Ligands at CySH-34: penicillamine, meso-2,3-dimercapto 
succinic acid, captopril (N -2-mercaptoethyl-1,2-diamino 
propane, disul?ramacetaminophen, cis 
dichlorodiammineplatinum9II) 
Miscellaneous: pyridoxal 5'-phosphate, Aquocobalamin 
form of vitamin B12, folate, ascorbate and its oxidation 
product dehydroascorbate, melatonin, a-melanotropin, 
gastrin, corticotropin, calcium, nickel, magnesium, and 
copper 
It is noted that the binding of some of these molecules to 
human serum albumin may be readily folloWed by detection 
procedures Well knoWn in the ?eld. For example, binding of 
tryptophan may easily be folloWed by ?uorescence. In addi 
tion, different ligands may either increase or decrease the 
af?nity of a second ligand for albumin to the extent multiple 
ligands are used. 
In accordance With the invention, the above human serum 
albumin binding compounds may be utiliZed in conjunction 
With human therapies Which can utiliZe camptothecins, and 
these albumin binding compounds inhibit binding of camp 
tothecin compounds to human serum albumin present in 
human blood and plasma, Which frees the camptothecin drug 
for therapeutic purposes. In addition, it is contemplated that 
the methods of the present invention may involve admini stra 
tion of a cocktail on one or more of these binders, or a single 
competing binding agent may be administered as needed. 
It is also contemplated that these albumin binding com 
pounds may be administered before, during, or after admin 
istration of the camptothecin agent. It is also contemplated 
that any camptothecin agent that binds albumin, regardless of 
the effect albumin has on the agent, Will still be useful in 
accordance With the invention since one goal of the therapy is 
to raise the vascular and tissue levels of total free drug, and 
this goal Will still be achieved even if albumin has an effect on 
the agent. 
The present invention thus provides a method of utilizing 
the ability of human serum albumin to avidly bind to a variety 
of small molecules so as to competitively attenuate negative 
effects of human serum albumin on the in vivo camptothecin 
compounds’ anti-cancer and anti-HIV activities. Because the 
human serum albumin binding site and af?nity for many 
small molecules have been Well characterized, many of these 
small molecules are ideal for in vivo administration and Will 
be useful in the present invention and can be utiliZed When it 
is necessary to target particular binding sites. A number of 
suitable small molecules such as those described above can 
thus be employed as human serum albumin binding competi 
tors to effect the displacement of camptothecin drugs and 
compounds, either in the lactone or carboxylate form. 
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In accordance With the invention, the inhibition of the 
binding of the camptothecin agent to human serum albumin 
Will thus enhance free drug levels in the blood and tissue. 
Given that a diverse assortment of small molecules binds to 
HSA, these small molecules may be administered singly or as 
a mixture With the camptothecin agent or compound to 
enhance their free drug levels. Additionally, as many of these 
small molecules exhibit pharmacological activity, it is also 
contemplated they may be utiliZed dually for their competi 
tive binding to human serum albumin and for their desired in 
vivo effect. Thus, agents such as methotrexate, AZT, and a 
number of additional small molecules Which have therapeutic 
effects apart from their ability to bind human serum albumin 
are preferably used in accordance With the invention to even 
further enhance free camptothecin drug levels and substan 
tially improve their respective biological effects in humans. 
These biological effects include their use as anti-cancer and/ 
or anti-HIV agents, as Well as their use in any other anti 
topoisomerase I-based therapy. 
The folloWing examples are provided only to exemplify 
various aspects of the preferred embodiments of the present 
invention. It Will thus be appreciated by those of skill in the art 
that the techniques and compositions disclosed in the 
examples Which folloW represent techniques and composi 
tions discovered by the inventors to function Well in the 
practice of the invention, and thus can be considered to con 
stitute preferred modes for its practice. 
HoWever, those of skill in the art Will also appreciate that 
the folloWing examples are only exemplary aspects of the 
present invention, the scope of Which is de?ned by the claims 
appended hereto, and thus many changes can be made in the 
speci?c embodiments Which are disclosed and still obtain a 
like or similar result Without departing from the spirit and 
scope of the invention. 
EXAMPLES 
Example 1 
HSA/Competition Experiments by Fluorescence 
Spectroscopic Methods 
Materials and Methods: 
The camptothecin used in the experiments Was obtained 
from Boehringer Ingelhem (Lot#95-002). Dimethyl Sulfox 
ide (HPLC grade, Aldrich, MilWaukee, Wis.) Was used to 
prepare stock solutions of camptothecin at various concen 
trations, Which Were stored in the dark at —200 C. Working 
solutions of 10x10“3 M camptothecin carboxylate and camp 
tothecin lactone Were prepared by diluting a stock solution of 
camptothecin in DMSO With PBS buffer at pH values of 10.0 
and 3.0, respectively. The Sigma Chemical Co. (St. Louis, 
Mo.) supplied the human serum albumin (HSA) employed in 
the binding experiments. A 2.5><10_3 M stock solution of 
HSA Was prepared in PBS buffer at a ?nal pH of 7.40:0.05. 
The concentration of the HSA Was determined on a Weight 
to-volume basis (g/L). A Milli-Q UV PLUS puri?cation sys 
tem (Bedford, Mass.) Was used to acquire high-purity Water. 
For the competition binding experiments, 3.0><10_3 M 
camptothecin carboxylate and 10x10‘3 M homocamptoth 
ecin Working solutions Were prepared. Caprylic acid obtained 
from Sigma Chemical Co. (Lot#72HO473) Was one of the 
competitive binders analyZed. Five different stock solutions 
of varied caprylic acid concentration Were made to satisfy 
concentration speci?cations discussed beloW. Another com 
petitive binder studied Was Ibuprofen obtained from Sigma 
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Chemical Co. (Lot#13HO7511). Four different stock solu 
tions of varied ibuprofen concentration Were prepared. Both 
caprylic acid and ibuprofen stock solutions Were made-up in 
PBS buffer at a ?nal pH of 7401005. 
Fluorescence Spectroscopy: 
Steady-state ?uorescence anisotropy measurements Were 
recorded using a SLM 9850 ?uorometer interfaced With an 
IBM computer. The samples Were excited at an excitation 
Wavelength of 370 nm by implementing an argon ion laser. 
The excitation monochromator bandWidth Was set to 4 nm. 
Fluorescence emission Was isolated from scattered light by 
utiliZing 400 nm long band-pass ?lters. 
For the camptothecin and homocamptothecin binding 
experiments With HSA, fourteen test tubes of varied HSA 
concentration Were prepared. Volumes of the 2.5><10_3 M 
HSA stock and PBS buffer pH of 7.40:0.05 Were combined 
in fourteen test tubes to create different HSA concentrations 
ranging from 0.5><10_5 M to 1.8><10_4M. The test tubes Were 
placed in a WWR Scienti?c Waterbath (Model 1235) set at 
37° C. for approximately ?ve minutes. FolloWing this, the 
?rst test tube Was removed and a 5 0x10“6 M concentration of 
the drug Was prepared by adding an appropriate volume of the 
1.0><10_3 M camptothecin or homocamptothecin (37° C) 
Working solution to the test tube. The drug and HSA solution 
Was immediately vortexed on a Vortex Genie 2TM from Fisher 
Scienti?c for approximately three to ?ve seconds. Immedi 
ately after, the solution Was transferred to a thermostatic (37° 
C.) sample cell and the anisotropy measurement Was 
recorded. The same procedure Was folloWed for the remain 
ing thirteen test tubes. For each tube, the anisotropy measure 
ment Was recorded Within one minute upon the addition of the 
drug. This short acquisition time secured that the anisotropy 
measurements re?ected the initial form of the drug added 
instead of a lactone-carboxylate equilibrium form. The 
results of the camptothecin and homocamptothecin HSA 
binding experiments can be seen in the Figures. 
The procedure folloWed for the competition binding 
experiments Was very similar to the description above. A 
3.0><10_3M camptothecin carboxylate Working solution Was 
prepared and kept at 37° C. Only ten of the fourteen test tubes 
described above Were prepared. The HSA concentration var 
ied from 5.0><10_6 to 75x10‘5 M. The maximum HSA con 
centration Was reduced due to background ?uorescence 
present from the HSA. Once the HSA/PBS solutions Were 
prepared, an appropriate volume of a competitor stock Was 
added to each tube. The competitor concentration Was iden 
tical for all ten test tubes. Caprylic acid competition concen 
trations of1.0><10_4 M, 1.0><10_3 M, 5 0x10“3 M, 1.0><10_2 M 
and 5.0><10_2M Were studied using the stock solutions dis 
cussed earlier. The same competition concentrations for Ibu 
profen Were studied excluding the 1 .0><10_2M. Once the com 
petitor Was added, the test tubes Were placed in the Waterbath, 
like before, and the measurements Were taken by employing 
the same technique described for the HSA binding experi 
ment. The results for the caprylic acid and ibuprofen compe 
tition binding With camptothecin carboxylate are shoWn on 
Figures CPT/HSA and CPT: Caprylic Acid/HSA and CPT/ 
HSA and CPT: Ibuprofen/HSA, respectively. 
The homocamptothecin carboxylate competition experi 
ments Were carried out using a 10x10“3 M homocamptoth 
ecin carboxylate Working solution at 37° C. Ten test tubes 
Were prepared using the same procedure described for the 
camptothecin competition experiments. Caprylic acid and 
ibuprofen competition concentrations of 10x10‘4 M, 10x 
10'3 M, 5.0><10_3 M, and 50x10“2 M Were studied. 
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Homocamptothecin carboxylate competition results are 
shoWn in Figures hCPT/HSA and hCPT: Caprylic Acid/HSA 
and hCPT/HSA and hCPT: Ibuprofen/HSA, respectively. 
Background ?uorescence from the HSA Was detected in all 
of the experiments. In the camptothecin carboxylate compe 
tition experiments With caprylic acid and ibuprofen, the maxi 
mum scattered light detected Was 8% and 5%, respectively. 
The homocamptothecin carboxylate competition experi 
ments displayed higher values of maximum scatter equal to 
13% and 15% for the caprylic acid and ibuprofen competi 
tion. In all cases, the percent of scattered light decreased With 
increasing competition concentration. 
Example 2 
Procedure of Competition Binding and Stability of 
9AC, DB172, DB67 and SN38 With the Presence of 
Various Drugs 
1. Materials 
Samples of 9AC, DB67, DB172 and SN38 Were obtained 
from various sources. Human serum albumin (HSA) Was 
purchased from Sigma Chemical (St. Louis, Mo.). Recovered 
human plasma Was obtained from Central Kentucky Blood 
Center (Lexington, Ky.) and stored at —20° C. Whole human 
blood Was obtained from a healthy male donor by draWing 
blood into sterile vacutainers containing heparin, to prevent 
clot formation. Ultra?ltration tubes Were purchased from 
Millipore. (Centrifree; MW cutoff 30,000). Triethylamine 
and HPLC-grade acetonitrile Was purchased from Fisher Sci 
enti?c (Fair LaWn, N.J., USA). High purity Water Was pro 
vided by a Milli-Q UV Plus puri?cation system (Millipore, 
Bedford, Mass., USA). Stock solutions of each drug Were 
prepared inA.C.S. spectrophotometric grade dimethylsulfox 
ide (DMSO; Aldrich, MilWaukee, Wis., USA) at a concentra 
tion of 2x10“3 M and stored in the dark at —20° C. until use. 
Phosphate buffered saline (PBS, pH 7.4) refers to an aqueous 
solution of 8 mM dibasic sodium phosphate (Na2HPO4), 1 
mM potassium phosphate monobasic crystal (KH2PO4), 137 
mM sodium chloride (NaCl) and 3 mM potassium chloride 
(KCl). 
2. HPLC apparatus: 
All HPLC analyses Were carried out on a Waters Alliance 
2690 Separations Module equipped With a WatersTM 474 
Scanning ?uorescence Detector, All separations Were carried 
out on a Waters symmetry® C18 5 pm 3.9><150 mm column 
With a Waters symmetry® C18 5 pm 3.9><20 mm guard col 
umn. For the separation of 9AC, Which is higher ?uorescence 
at loW pH and the acidi?cation of mobile phase before sepa 
ration Will change 9AC carboxylate form to lactone form, the 
postcolumn acidi?cation Was employed. The postcolumn 
acidi?cation can separation carboxylate and lactone before 
acidify and acidify the mobile phase by pump 0.5N HCl at a 
?oW rate 0.5 ml/min before the drug goes into the detector. A 
XterraTM MS Cl 8 5 pm 3.9><150 mm column (stable at loW and 
high pH) Was used for postcolumn acidi?ation to stable the 
baseline. For the separation of 9AC, mobile phase consisted 
of 20% acetonitrile and 80% of an aqueous buffer containing 
triethylamine and acetate. The triethylamine/acetate buffer 
(pH 5.5) contained 2% triethylamine added to distilled, 
deioniZed Water With pH adjustment to 5.5 made With con 
centrated acetic acid. Fluorescence excitation for 9AC Was set 
at 380 nm and emission at 450 nm. For DB172, the mobile 
phase consisted of 57% acetonitrile and 43% triethylamine/ 
acetate buffer. Excitation and emission detectors settings of 
371 nm and 428 nm, respectively, Were used. For DB67, the 
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mobile phase consisted of 41% acetonitrile and 59% triethy 
lamine/acetate buffer. Excitation and emission detectors set 
tings of 380 nm and 560 nm, respectively, Were used. For 
SN38, the mobile phase consisted of 25% acetonitrile and 
75% triethylamine/acetate buffer. Excitation and emission 
detectors settings of 383 nm and 560 nm, respectively, Were 
used. FloW rates of l min/ml Were used in all experiments. 
The mobile phase Was degassed by ?lter through a membrane 
?lter (0.45 pm, Millipore). Fluorescence output signal Was 
monitored and integrated using Millennium32 Chromatogra 
phy Manager softWare. 
3. Protein Binding Studies: 
Preparation of Standard Solution 
A stock solution containing 2 mM of the drug of the interest 
in DMSO Was prepared and stored at —200 C. For 9AC and 
DB67, an aliquot of this stock Was added to PBS pH 10.0 to 
form 100 pM carboxylate standard solutions. 
Protein Binding Studies of 9-AC Carboxylate 
The present studies determined the protein binding to the 
carboxylate form of 9-AC. Initial experiments Were run to 
determine the amount of 9-AC carboxylate lost during protein 
binding studies due to adhesion to the ultra?ltration mem 
brane. PBS (990 pl) at pH 7.4 Was spiked With 9-AC carboxy 
late to form 1 pM 9-AC solution. After vortexing for 30 
seconds, 500 pl of the solution Was transferred to an ultra?l 
tration device and centrifuged for 15 minutes at 4500 rpm. A 
100 pl aliquot of the ?ltrate Was added to 600 pl ice-cold 
methanol and vortexed. A 500 pl aliquot of the supernatant 
Was removed and mixed With 25 pl 12 N HCl. The suspension 
Was mixed With 1 ml of Water, vortexed, and injected (100 pl) 
onto the HPLC. The same protocol Was repeated With 100 pl 
total (1 pM 9-AC before ultra?ltration). The percentage 
recovery Was obtained: the ?ltrate concentration divided by 
the total concentration. 
Protein Binding of 9-AC Carboxylate to HSA (30 mg/ml), 
Human Plasma With or Without the Presence of Various 
Drugs. 
Protein binding studies using HSA, human plasma With 
and Without the presence of various drugs Were conducted in 
a similar manner. HSA Were prepared With PBS (pH 7.4). A 
mount of different drug (phenylbutaZone, ibuprofen, caprylic 
acid , aspirin, Warfarin-Na salt, L-tryptophan) Was added to 
HSA or human plasma to form different concentration of 
drug, In the test tube, 990 pl HSA solution or human plasma 
With or Without various Was spiked With 9-AC carboxylate to 
form 1 pM 9-AC solution. After vortexing for 30 seconds, 
500 pl of the solution Was transferred to an ultra?ltration 
device and centrifuged for 15 minutes at 4500 rpm. A 100 pl 
aliquot of the ?ltrate Was added to a 600 pl ice-cold methanol, 
vortexed and centrifuged at 8000 rpm for 30 seconds. A 500 
pl aliquot of the supernatant Was removed and mixed With 25 
pl 12 N HCl. Subsequently, 1 ml of Water Was added to the 
suspension and the mixture Was vortexed and injected 
(100 pl) onto the HPLC. The same protocol Was repeated With 
100 pl total (1 ppM 9-AC before ultra?ltration). The total 
drug concentration Was corrected for the apparent drug loss 
due to adsorption of the drug to the ultra?ltration membrane 
using the equation: 
Corrected total concentration:detennined total con 
centrationxthe percentage recovery. 
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The bound concentration Was obtained by calculating differ 
ence: corrected total concentration minus free concentration. 
All experiments Were run in triplicate. 
Protein Binding Studies of DB67 Carboxylate 
The present studies determined the protein binding to the 
carboxylate form of DB67. Initial experiments Were run to 
determine the amount of DB67 carboxylate lost during pro 
tein binding studies due to adhesion to the ultra?ltration 
membrane. PBS (990 pl) at pH 7.4 Was spiked With DB67 
carboxylate to form 1 pM DB67 solution. After vortexing for 
30 seconds, 500 pl of the solution Was transferred to an 
ultra?ltration device and centrifuged for 15 minutes at 4500 
rpm. A 100 pl aliquot of the ?ltrate Was added to 600 pl 
ice-cold methanol and vortexed. A 500 pl aliquot of the super 
natant Was removed diluted With 500pl PBS (pH 12) and 
injected (10 pl) onto the HPLC. The same protocol Was 
repeated With 100 pl total (1 pM DB67 before ultra?ltration). 
The percentage recovery Was obtained: the ?ltrate concentra 
tion divided by the total concentration. 
Protein Binding of DB67 Carboxylate to HSA (30 mg/ml), 
Human Plasma With or Without the Presence of Caprylic Acid 
Protein binding studies using HSA, human plasma With 
and Without the presence of various drugs Were conducted in 
a similar manner. HSA Were prepared With PBS (pH 7.4). A 
mount of caprylic acid Was added to HSA or human plasma to 
form different concentration of drug, In the test tube, 990 pl 
HSA solution or human plasma With or Without various Was 
spiked With DB67 carboxylate to form 1 pM DB67 solution. 
After vortexing for 30 seconds, 500 pl of the solution Was 
transferred to an ultra?ltration device and centrifuged for 15 
minutes at 4500 rpm. A 100 pl aliquot of the ?ltrate Was added 
to a 600 pl ice-cold methanol, vortexed and centrifuged at 
8000 rpm for 30 seconds. A 500 pl aliquot of the supernatant 
Was removed and diluted With 500 pl PBS (pH 12) and 
injected (10 pl) onto the HPLC. The same protocol Was 
repeated With 100 pl total (1 pM DB67 before ultra?ltration). 
The total drug concentration Was corrected for the apparent 
drug loss due to adsorption of the drug to the ultra?ltration 
membrane using the equation: 
Corrected total cOncentratiOnIdeteImined total con 
centrationxthe percentage recovery. 
The bound concentration Was obtained by calculating differ 
ence: corrected total concentration minus free concentration. 
All experiments Were run in triplicate. 
Lactone Stability Studies 
Lactone and Carboxylate Peak Area Ratio 
A stock solution containing 2mM of interested drug Was 
prepared and stored at —200 C. The stock solution Was diluted 
5-time With DMSO to form 0.4 mM stock. 2pl 0.4 mM stock 
Was added to 798 pl DMSO to form 1 pM Lactone form, or 
added to 798 pl PBS pH 10.0 to form 1 pM carboxylate form, 
and injected onto the column. The ratio of molar ?uorescence 
intensities of the lactone to carboxylate form (k) is calculated 
as folloWing: 
Lactone/carboxylate ratio (k):average peak area of 
lactone/average peak area of carboxylate 
Stability Study of 9AC, DB67, DBl72 and SN38 in Human 
Whole Blood, HSA or Human Plasma With or Without 
Caprylic Acid 
Weigh amount of caprylic acid and added to HSA, human 
plasma and human Whole blood to form a certain concentra 
tion of caprylic acid (1 mM, 2 mM, 10 mM, 25 mM, 50 mM 
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and 100 mM). For HSA and human plasma, incubate the HSA 
or human plasma With or Without caprylic acid at 370 C. and 
adjust pH to7.4. For human Whole blood, it Will form partici 
pate With caprylic acid When adjust pH With HCl or NaOH. 
So, ?rst adjust pH a little below 7.4 and then add caprylic acid 
to form pH 7.4 With caprylic acid in Whole blood. A 5 pl 0.4 
mM interest drug solution Was added to 1995 pl of HSA 
human plasma or human Whole blood that had previous been 
incubated at 370 C. and adjusted to pH 7.4 to form a 1 pM 
solution. At each respective time interval, a 150 pl volume 
Was removed from the incubation tube and added to 600 pl of 
ice-cold methanol (—200 C.), vortex-mixed for 20 s and cen 
trifuged at 4000 g for 1 min. The supernatant Was directly 
injected onto the HPLC column immediately. Aliquots Were 
taken and HPLC analyses Was performed at times of 1, 10, 20, 
30, 60, 120 and 180 minutes, respectively. The fraction of 
lactone form Was calculated as: 
Fraction of lactone:lactone area/(lactone area+carboxylate 
area*k), Where k is the response factor de?ned as the ratio of 
molar ?uorescence intensities of the lactone to carboxylate 
form. 
In the Tables appended hereto, competition binding and 
stability of 9AC, DB172, DB67 and SN38 With the presence 
of various drugs is shoWn, including Table 1.1 (Protein bind 
ing of 9AC carboxylate (1 pM) in HSA and human plasma) 
and Table 1.2 (Protein binding of DB67 carboxylate (1 pM) 
in HSA and human plasma). 
Competition binding and stability of 9AC, DB172, 
DB67 and SN38 With the presence ofvarious drugs 
1. Competition binding 
1.1 Protein binding of 9AC carboxylate (1 pM) in HSA and human plasma 
Matrix Compound added Percent 9AC bound 
HSA (1 mgml) No 94.26 1 0.25 
HSA (1 mgml) Phenylbutazone (0.162 mM) 81.52 1 1.16 
HSA (1 mgml) Ibuprofen (480 mM) 0.00 r 0.00 
HSA (1 mgml) Caprylic acid (347 mM) 0.00 r 0.00 
HSA (30 mg/ml) No 100.00 1 0.00 
HSA (30 mg/ml) Ibuprofen (10 mM) 24.82 1 0.99 
HSA (30 mg/ml) Caprylic acid (10 mM) 83.34 1 0.88 
Human plasma No 100.00 1 0.00 
Human plasma Phenylbutazone (0.2 mM) 99.90 1 0.04 
Human plasma Aspirin (10 mM) 97.98 1 0.12 
Human plasma Warfarin-Na salt (10 mM) 86.44 1 0.67 
Human plasma L-Tryptophan (10 mM) 99.59 1 0.03 
Human plasma Ibuprofen (100 mM) 0.00 r 0.00 
Human plasma Ibuprofen (10 mM) 43.06 1 0.76 
Human plasma Ibuprofen (1 mM) 99.82 1 0.04 
Human plasma Caprylic acid (100 mM) 0.00 r 0.00 
Human plasma Caprylic acid (80 mM) 15.05 1 3.17 
Human plasma Caprylic acid (60 mM) 5.14 r 2.38 
Human plasma Caprylic acid (40 mM) 22.73 1 1.32 
Human plasma Caprylic acid (20 mM) 74.04 1 1.82 
Human plasma Caprylic acid (10 mM) 89.62 1 0.18 
Human plasma Caprylic acid (1 mM) 99.86 1 0.04 
1.2 Protein binding ofDB67 carboxylate (1 pM) in HSA and human 
plasma 
Matrix Compound added Percent DB67 bound 
HSA (30 mg/ml) No 99.22 1 0.23 
HSA (30 mg/ml) Caprylic acid (100 mM) 39.09 1 0.88 
HSA (30 mg/ml) Caprylic acid (10 mM) 75.52 1 0.69 
Human plasma No 98.58 1 0.09 
Human plasma Caprylic acid (100 mM) 53.39 1 1.64 
Human plasma Caprylic acid (10 mM) 78.81 1 0.31 
Human plasma Caprylic acid (1 mM) 96.40 1 0.06 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
18 
What is claimed is: 
1. A method for increasing the free drug levels of a camp 
tothecin drug that binds human serum albumin (HSA) during 
anti-topoisomerase I-based therapy in humans, said method 
comprising administering, to a human or animal patient in 
need of said therapy, at least one HSA-binding compound, 
Wherein said HSA-binding compound is a phospholipid, so as 
to block the camptothecin binding site on HSA and thus 
reduce the binding of the camptothecin drug to HSA in human 
blood or plasma so that the free drug levels of the camptoth 
ecin drug Will be increased and so that greater levels of the 
camptothecin Will reach the drug target at the treatment site, 
Wherein the HSA-binding compound is administered sepa 
rately from the camptothecin drug. 
2. The method according to claim 1, Wherein the phospho 
lipid is selected from the group consisting of lysolecithins and 
oleoyllysophosphatidic acid. 
3. The method according to claim 1, Wherein the HSA 
binding compound is administered intravenously or orally. 
4. The method according to claim 1, Wherein the HSA 
binding compound is administered before, simultaneously 
With, or after administration of the camptothecin drug. 
5. The method according to claim 1, Wherein the binding of 
the HSA-binding compound to HSA occurs by covalent or 
non-covalent means. 
6. The method according to claim 1, Wherein the binding of 
the HSA-binding compound to HSA results in the direct 
displacement of the camptothecin drug from its HSA binding 
site. 
7. The method according to claim 1, Wherein the binding of 
the HSA-binding compound to HSA results in the displace 
ment of the camptothecin drug from its HSA binding site by 
allosteric inhibition. 
8. The method according to claim 1 Wherein the camptoth 
ecin drug is selected from the group consisting of camptoth 
ecins that contain either an E-ring ot-hydroxy lactone phar 
macophore or an E-ring [3-hydroxy lactone pharmacophore, 
homocamptothecins, homosilatecans, 9-aminocamptothecin, 
10-hydroxycamptothecin, 10,1 1 -methylenedioXy-camptoth 
ecin, 9-nitro- 10,11-methylenedioxycamptothecin, 9-chloro 
10, 1 1 -methylenedioXycamptothecin, 9-amino-10,1 1-meth 
ylenedioXy-campto-thecin, 9-nitrocamptothecin, topotecan, 
and combinations of the above. 
9. A method for improving the free lactone levels of at least 
one camptothecin drug that binds in the carboxylate form to 
HSA during anti -topoisomerase I-based therapy, said method 
comprising administering, to a human or animal patient in 
need of said therapy, at least one HSA-binding compound, 
Wherein said HSA-binding compound is a phospholipid, so as 
to block the camptothecin binding site on HSA and thus 
reduce the binding of the camptothecin drug to HSA in human 
blood or plasma so that the free lactone levels of the camp 
tothecin drug Will be increased in human blood or plasma and 
so that greater levels of the camptothecin Will reach the drug 
target at the treatment site, Wherein the HSA-binding com 
pound is administered separately from the camptothecin 
drug. 
10. The method according to claim 9, Wherein the HSA 
binding compound is administered intravenously or orally. 
11. The method according to claim 9, Wherein the HSA 
binding compound is administered before, simultaneously 
With, or after administration of the camptothecin agent. 
12. The method according to claim 9, Wherein the binding 
of the HSA-binding compound to HSA occurs by covalent or 
non-covalent means. 
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13. The method according to claim 9, wherein the binding 
of the HSA-binding agent to HSA results in the direct dis 
placement of the camptothecin drug from its HSA binding 
site. 
14. The method according to claim 9, Wherein the binding 
of the HSA-binding agent to HSA results in the displacement 
of the camptothecin drug from its HSA binding site by allos 
teric inhibition. 
15. A method for enhancing the cellular uptake and cellular 
concentration of the camptothecin drug that binds to HSA 
during anti-topoisomerase l-based therapy, said method com 
prising administering, to a human or animal patient receiving 
said therapy, at least one HSA-binding compound, Wherein 
said HSA-binding compound is a phospholipid, so as to block 
the camptothecin binding site on HSA and thus reduce the 
binding of the camptothecin drug to HSA in human blood or 
plasma so that the cellular uptake and cellular concentration 
of the camptothecin drug Will be enhanced in human blood or 
plasma and so that greater levels of the camptothecin drug 
Will reach the drug target at the treatment site, Wherein the 
HSA-binding compound is administered separately from the 
camptothecin drug. 
16. The method according to claim 15, Wherein the HSA 
binding compound is administered intravenously or orally. 
17. The method according to claim 15, Wherein the HSA 
binding compound is administered before, simultaneously 
With, or after administration of the camptothecin agent. 
18. A method for enhancing the therapeutic effect of a 
camptothecin drug that binds human serum albumin (HSA) 
during anti-topoisomerase l-based therapy, said method com 
prising administering, to a human or animal patient in need of 
said therapy, at least one HSA-binding compound, Wherein 
said HSA-binding compound is a phospholipid, so as to block 
the camptothecin binding site on HSA and thus reduce the 
binding of the camptothecin drug to HSA in human blood or 
plasma so that the therapeutic effect of the camptothecin drug 
Will be enhanced and so that greater levels of the camptoth 
ecin drug Will reach the drug target at the treatment site, 
Wherein the HSA-binding compound is administered sepa 
rately from the camptothecin drug. 
19. The method according to claim 18, Wherein the HSA 
binding compound is administered intravenously or orally. 
20. The method according to claim 18, Wherein the HSA 
binding compound is administered before, simultaneously 
With, or after administration of the camptothecin drug. 
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21. The method according to claim 1, Wherein the HSA 
binding compound has anti-tumor or tumoricidal activity. 
22. The method according to claim 1, Wherein the HSA 
binding compound has anti-HIV activity. 
23. The method according to claim 1, Wherein the HSA 
binding compound that has the ability to enhance the anti 
topoisomerase l-based therapy in addition to the ability to 
bind HSA. 
24. A method for improving the effectiveness of a thera 
peutic treatment regimen using a camptothecin drug that 
binds to HSA during anti-topoisomerase l-based therapy 
comprising administering to a human or animal patient in 
need of said therapy a HSA-binding compound, Wherein said 
HSA-binding compound is a phospholipid, so as to block the 
camptothecin binding site on HSA and thus reduce the bind 
ing of the camptothecin drug to HSA in human blood or 
plasma so that the effectiveness of the therapeutic treatment 
regimen of the camptothecin drug Will be improved and so 
that greater levels of the camptothecin Will reach the drug 
target at the treatment site, Wherein the HSA binding com 
pound is administered separately from the camptothecin 
drug. 
25. The method according to claim 24 Wherein said thera 
peutic treatment regimen comprises therapeutic treatment for 
AIDS. 
26. The method according to claim 24 Wherein said thera 
peutic treatment regimen comprises therapeutic treatment for 
cancer. 
27. The method according to claim 1 Wherein the HSA 
binding compound is administered in an amount of in an 
amount of at least 0.1 mM. 
28. The method according to claim 9 Wherein the HSA 
binding compound is administered in an amount of in an 
amount of at least 0.1 mM. 
29. The method according to claim 15 Wherein the HSA 
binding compound is administered in an amount of in an 
amount of at least 0.1 mM. 
30. The method according to claim 18 Wherein the HSA 
binding compound is administered in an amount of in an 
amount of at least 0.1 mM. 
31. The method according to claim 24 Wherein the HSA 
binding compound is administered in an amount of in an 
amount of at least 0.1 mM. 
